financing

News

Respiratory biotech Upstream joins Nasdaq IPO surge

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.

News

US puts $25m behind Cellino's cell and tissue printing tech

Cellino Biotech has received funding from the US government to develop a scalable biomanufacturing platform for personalised regenerative medicines derived from patients' own stem cells.

News

Armed with $100m funding, F2G prepares to refile antifungal

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA.

News

Terns files $125m financing after positive obesity data

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi

News

Hand holding a pen following the peaks and troughs of a graph on screen

BioAge's $100m IPO, and other biotech financings

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable privat

News

ArsenalBio raises $325m for programmable CAR-T platform

Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro

Respiratory biotech Upstream joins Nasdaq IPO surge

US puts $25m behind Cellino's cell and tissue printing tech

Armed with $100m funding, F2G prepares to refile antifungal

Terns files $125m financing after positive obesity data

BioAge's $100m IPO, and other biotech financings

ArsenalBio raises $325m for programmable CAR-T platform

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

financing

Editor's Picks